循环肿瘤细胞PD-L1表达在非小细胞肺癌免疫治疗中的应用  

Clinical utility of PD-L1 expression in circulating tumor cells in non-small cell lung cancer patients treated with immunotherapy

作　　者：王亚东 杨笑盈 贾梓淇 邴钟兴[1] 杨华夏[3] 杨延莲[4] 胡志远[4] 李单青 梁乃新[1] WANG Yadong;YANG Xiaoying;JIA Ziqi;BING Zhongxing;YANG Huaxia;YANG Yanlian;HU Zhiyuan;LI Shanqing;LIANG Naixin(Department of Thoracic Surgery,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing,100730,P.R.China;Peking Union Medical College,Eight-Year MD Program,Beijing,100005,P.R.China;Department of Rheumatology and Clinical Immunology,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing,100730,P.R.China;National Center for Nannoscience and Technology,Beijing,100190,P.R.China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院胸外科,北京100730 [2]北京协和医学院,北京100005 [3]中国医学科学院北京协和医学院北京协和医院风湿免疫科,北京100730 [4]国家纳米科学中心,北京100190

出　　处：《中国胸心血管外科临床杂志》2021年第1期110-115,共6页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：北京市自然科学基金面上项目(7182132);国家人口与健康科学数据共享服务平台肿瘤专题数据服务项目(NCMI-ABD02-201809;NCMI-YF02N-201906);北京市科委重大课题(Z171100002017013);北京协和医院青年基金(PUMCH-2016-2.25;HI626500);中国医科院青年人才奖励项目(2018RC320005);北京市东城区优秀人才培养资助项目(2018-DCQYXRCXM-012);北京市大学生创新项目(2019zlgc0629)。

摘　　要：肺癌是全世界发病率及病死率最高的恶性肿瘤。近年来,针对程序性死亡受体1(programmed cell death 1,PD-1)及其配体(programmed cell death-ligand 1,PD-L1)的免疫检查点抑制剂治疗显著改善了非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的预后。然而在非选择人群中免疫治疗的客观应答率仅约20%,因此选择出免疫治疗潜在的获益人群非常重要。通过免疫组织化学检测肿瘤组织中PD-L1的表达可以在一定程度上预测免疫治疗的疗效,但是其仍有一定的局限性。最新临床研究表明循环肿瘤细胞(circulating tumor cell,CTC)上PD-L1的表达(PD-L1 expression in circulating tumor cells,CTC-PD-L1)是一种潜在的独立生物标志物,其可为NSCLC的免疫治疗提供重要信息。本文将对CTC-PD-L1检测技术及其在NSCLC患者免疫治疗效果中的预测价值及最新临床研究进展进行综述。Lung cancer is the most frequent cancer and the leading cause of cancer death all around the world.Anti-programmed cell death 1(PD-1)/programmed cell death-ligand 1(PD-L1)therapies have significantly improved the outcomes of non-small cell lung cancer(NSCLC)patients in recent years.However,the objective response rate in nonscreened patients is only about 20%.It is very important to screen out the potential patients suitable for immunotherapy.Immunohistochemical staining of tumor tissue biopsies with PD-L1 antibodies can predict the therapeutic response to immunotherapy to some extent,but it still has some limitations.Recently some clinical studies have shown that PD-L1 expression in circulating tumor cells(CTC-PD-L1)is a potential independent biomarker and may provide important information for immunotherapy in NSCLC.This article will review technology for CTC-PD-L1 detection and the predictive value of CTC-PD-L1 for immunotherapy in NSCLC and review the latest clinical research progress.

关 键 词：循环肿瘤细胞 程序性死亡配体-1 非小细胞肺癌 免疫治疗 综述 

分 类 号：R734.2[医药卫生—肿瘤]